SRSF1 and cancer: The discovery (log-rank test p = 0.062), validation (log-rank test p = 0.03), and combined patient cohort (Cox PH p = 0.012; HR = 2.1; log-rank test p = 0.005) analyses are provided in Fig 3D–3Fand S7 Table CN gains in SRSF1 from The Cancer Genome Atlas (TCGA) were interrogated for correlation with survival (S3 Fig to evaluate the specificity of SRSF1 CN gains associating with survival in other cancer indications.